Antag Therapeutics is a Copenhagen-based preclinical stage biotechnology company focused on developing therapies for dietary-related metabolic diseases. The company’s current lead therapy is a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist for inducing weight loss in obese patients with Type-2 Diabetes. The Company’s technology is based upon decades of incretin physiology and diabetes research from the laboratories of Professors Mette Rosenkilde and Jens Juul Holst at the University of Copenhagen, which played a pivotal role
in the establishment of dipeptidyl peptidase 4 (DPP-4) inhibitor and glucagon-like peptide-1 (GLP-1) agonist drug classes.
BioKier is developing a proprietary oral treatment for diabetes based on understanding the mechanism of the anti-diabetic effects of metabolic surgery previously described and malabsorptive. Independent of its weight loss effect, metabolic surgery substantially improves or even resolves diabetes within days in 80 to 90 percent of obese Type 2 diabetes patients. This surgery is equally effective in non-obese diabetes patients. BioKier has devised a proprietary method to mimic the effects of intestinal shortening surgery and potentially improve or resolve diabetes without the physical trauma and cost of bariatric surgery. Diabetes has long been recognized as a major contributor to the development of cardiovascular disease. Heart disease and stroke are the major causes of death and disability among people with Type 2 diabetes.
GI Windows is a clinical-stage medical device company developing a non-surgical approach to create anastomoses in the GI tract. Their patented self-assembling magnets are designed to enable an incision-less and durable intestinal bypass to treat chronic diseases, such as Type-2 Diabetes and Obesity, without the cost and invasiveness of surgical interventions.
Gila Therapeuticsis a clinical-stage biotherapeutic company focused on pharmacological treatment of obesity employing intra-oral application of naturally occurring satiety hormones to induce early fullness, leading to weight loss. Targeting a unique and recently discovered direct neural pathway between the tongue and brain, Gila is developing formulations that when applied to the tongue prior to meals directly stimulates the brain’s satiety centers intended to reduce food intake without any systemic exposure.
Gila, based in Minnesota, was founded in 2014 by Andres Acosta, Sergei Zolotukhin and Thomas Vasicek who serves as the CEO.
Kantum Pharma is a privately-held biopharmaceutical company focused on developing therapies to prevent or reduce inflammaton initiated through the uridine diphosphate (UDP)-glucose/P2Y14 purinergic receptor signaling pathway in organs such as the kidneys, lungs and female reproductive tract. The Company’s initial small molecule therapeutic program, KB-1801, has been shown preclinically to reduce renal inflammation and has the potential to transform the treatment paradigm for acute kidney injury AKI. Kantum is pursuing additional applications of this technology for therapeutics and diagnostics to ameliorate the impact of numerous inflammatory disorders.
Acute kidney injury (AKI) is characterized by an abrupt loss of kidney function—this common medical complication affects 4,000,000 and kills 300,000 people every year in the US alone. AKI affects one in five hospitalized adults and one in three hospitalized children, and is associated with annual healthcare costs in the USA exceeding $10B. AKI occurs in roughly 30% of all cardiac surgeries, and Kantum Pharma is uniquely positioned to develop a novel specific AKI therapeutic to reduce its incidence, severity and sequelae. In parallel, Kantum will develop a test to enable doctors to diagnose AKI before it develops. This combination of early diagnosis and specific therapy to reduce or prevent AKI incidence and progression promises to transform clinical outcomes for patients undergoing cardiac surgery.
Mellitus is dedicated to advancing diabetes detection and monitoring through products based on GCD59, a biomarker of glycemic load that is unique because of its direct relationship to the complications of diabetes. Our premier application is a patient-friendly test for gestational diabetes, enabling more timely intervention to improve the health of both mother and child. We plan to commercialize our products through strategic partners as we expand indications to benefit all individuals with diabetes.